论文部分内容阅读
目的:分析缩宫素、米索前列醇联合疗法在子宫收缩乏力性产后出血防治中的临床效果。方法:随机选取所在医院2014年8月—2016年4月68例临盆产妇,按照随机方法进行分组。其中,实验组(n=34)产妇采用缩宫素、米索前列醇联合疗法对产后出血进行预防和处理,对照组(n=34)产妇则单纯给予缩宫素进行防治,对2组产妇临床治疗情况进行比较。结果:实验组无子宫收缩乏力性产后出血病例,对照组子宫收缩乏力性产后出血发生率为14.71%,2组差异显著(P<0.05);实验组用药2h、6h、12h子宫出血量均明显低于对照组,且发热、寒颤、血压升高等不良反应发生率明显低于对照组,2组疗效差异明显(P<0.05)。结论:缩宫素、米索前列醇联合疗法防治子宫收缩乏力性产后出血,临床效果显著,且用药安全,值得临床广泛推广。
Objective: To analyze the clinical effect of combination of oxytocin and misoprostol in the prevention and treatment of postpartum hemorrhage due to uterine atony. Methods: Randomly selected the hospital from August 2014 to April 2016 68 cases of childbirth, according to a randomized method of grouping. Among them, the experimental group (n = 34) adopted oxytocin and misoprostol combination therapy for the prevention and treatment of postpartum hemorrhage in the experimental group (n = 34), and oxytocin alone in the control group (n = 34) Clinical treatment compared. Results: In the experimental group, there were no cases of postpartum hemorrhage with uterine atony. The incidence of postpartum hemorrhage in the control group was 14.71%, which was significantly different between the two groups (P <0.05). The amount of uterine bleeding in the experimental group was significantly higher at 2h, 6h and 12h The incidence of adverse reactions such as fever, shivering and blood pressure were significantly lower than those in the control group (P <0.05). Conclusion: Combination therapy of oxytocin and misoprostol can prevent postpartum hemorrhage due to uterine atony. The clinical effect is significant and the drug is safe. It is worth widely clinical application.